S1PR1 and myeloid sarcoma: In MS only siponimod, an S1P1/S1P5 receptor modulator, which is not currently licensed, has shown a modest effect in a phase III trial (EXPAND) in secondary- progressive MS, preventing disability progression by 21% in two years [294].